Compound Cell Lines – IC50 mM ± S.E.M Primary culture
  HL-60 SF-295 HCT-8 Human
Lymphocytes
2a
(LASSBio-1599)
> 300 208.67 ±7.28

173.41 ±5.91

194.3 ±2.17
2b
(LASSBio-1598)
> 300 287.53 ±3.15 > 300 > 300
2c
(LASSBio-1597)
74.40 ±9.80 107.64 ±5.10 39.61 ±7.05 > 300
6
(LASSBio-1724)
> 300 > 300 > 300 > 300
7
(LASSBio-1725)
> 300 > 300 > 300 > 300
8
(LASSBio-1726)
> 300 > 300 > 300 > 300
9
(LASSBio-1723)
> 300 > 300 > 300 > 300
10
(LASSBio-1727)
35.75 ±2.51 > 300 > 300 > 300
Imatinib 22.81 ±3.11 41.53 ±5.73 34.03 ±4.11 > 300
Doxorubicin 0.04 ±0.01 0.48 ±0.02 0.02 ±0.01 0.37 ±0.01
HL-60 (human leukemia); SF-295 (human glioblastoma); HCT-8 (human colorectal carcinoma)
Table 2: Antiproliferative activity of carboxamides 2a-c, imatinib and doxorubicin (positive control) against HL-60, SF-295, HCT-8 tumor cell lines and their cytotoxic activity against primary culture of human lymphocytes.